Physician profile
Anna Frisch
NPI 1235317389
$9,150.53
in general payments reported to CMS, 2019-2025
43 companies · $1,160 in 2025
The $1,160 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,754 · 2020: $842 · 2021: $894 · 2022: $1,296 · 2023: $1,586 · 2024: $1,618 · 2025: $1,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,314 · Consulting Fee: $1,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,313.77 |
| Consulting Fee | $1,050.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,380.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,129.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Ibsa Pharma INC. | $1,124.07 | 2019-2024 | Tirosint |
| Xeris Pharmaceuticals, INC. | $679.84 | 2020-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $581.59 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $561.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.38 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $488.22 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $305.24 | 2019-2025 | Unithroid |
| Abbott Laboratories | $299.23 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $254.53 | 2019-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $250.94 | 2019-2021 | |
| Insulet Corporation | $195.43 | 2019-2024 | Omnipod |
| Vivus LLC | $164.49 | 2019-2024 | Qsymia, Pancreaze |
| Corcept Therapeutics | $121.94 | 2022-2025 | Korlym |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Frisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.